Skip to main content
Bioceltix S.A. logo

Bioceltix S.A. — Investor Relations & Filings

Ticker · BCX ISIN · PLBCLTX00019 LEI · 259400QZD5JYK8SLZU51 WAR Manufacturing
Open in API
Filings indexed 270 across all filing types
Latest filing 2022-02-09 Regulatory Filings
Country PL Poland
Listing WAR BCX

About Bioceltix S.A.

https://bioceltix.com/en/

Bioceltix S.A. is a biopharmaceutical company that develops stem cell-based medicinal products for veterinary use. The company focuses on creating therapies that utilize Mesenchymal Stem Cells (MSCs) as the active pharmaceutical ingredient. Its product pipeline is aimed at treating immunological and inflammatory conditions in companion animals, including dogs, cats, and horses. A key area of development includes treatments for conditions such as atopic dermatitis in dogs and degenerative joint disease.

Recent filings

Filing Released Lang Actions
Zawarcie umowy na przeprowadzenie badania na pacjentach klinicznych dla kandydata na produkt leczniczy BCX-CM-AD - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is a formal announcement in Polish (Raport bieżący) referencing a previous report and detailing a newly signed agreement (Umowa) for clinical trials related to a drug candidate (BCX-CM-AD). This concerns a significant business development, specifically related to product development and potential commercialization. This type of material, detailing a specific business transaction or development that is material to the company, often falls under general regulatory announcements or specific transaction categories. Since there is no specific category for 'Material Business Development' or 'Contract Signing', and it is not a standard financial report (10-K, IR, ER), nor a management change (MANG) or director dealing (DIRS), it best fits the general regulatory announcement category, RNS, as it is a 'Raport bieżący' (Current Report) detailing a material event.
2022-02-09 Polish
Aktualizacji strategii rozwoju na lata 2022-2024 - Content (PL)
Management Reports Classification · 1% confidence The document is a formal announcement by the Management Board ("Zarząd") of Bioceltix S.A. detailing an updated development strategy for 2022-2024, including specific R&D projects, capital expenditure estimates (up to 67 million PLN), hiring plans, and future financing needs (60 million PLN to be raised externally). Crucially, the final paragraph states that the Management Board plans to submit a resolution to shareholders at the upcoming General Meeting regarding a capital increase via new share issuance and seeking admission of shares to a regulated market. This content strongly suggests a strategic update that directly impacts capital structure and requires shareholder approval, often associated with financing activities or major strategic shifts. Since it details future financing needs and plans for a capital increase to be voted on, it aligns best with 'Capital/Financing Update' (CAP). It is not a standard financial report (10-K, IR), an earnings release (ER), or a proxy statement (PSI), but a strategic announcement detailing capital requirements.
2022-02-08 Polish
Zawiadomienie o zmniejszeniu udziału w liczbie głosów poniżej 5%
Major Shareholding Notification Classification · 1% confidence The document is a formal notification dated February 7, 2022, from Aviva Investors Poland TFI SA regarding a change in shareholding in Bioceltix S.A. The key phrase is 'zawiadomienie o zmniejszeniu udziału w liczbie głosów poniżej 5%' (notification of a reduction in the share of votes below 5%). This explicitly details a change in significant share ownership, crossing a regulatory threshold (5%). This aligns perfectly with the definition of Major Shareholding Notification (MRQ). The document cites Polish public offering laws (art. 69 of the relevant Act), confirming its regulatory nature regarding ownership changes.
2022-02-08 Polish
Zawiadomienie o zmianie udziału w ogólnej liczbie głosów na Walnym Zgromadzeniu Emitenta - Content (PL)
Major Shareholding Notification Classification · 1% confidence The document text is very short (668 characters) and explicitly states that a notification ('zawiadomienie') regarding a decrease in the total number of votes at the General Meeting ('Walnym Zgromadzeniu Spółki') has been received, and the content of this notification is attached as an appendix to the current report. This structure—announcing the receipt of a filing/notification and referencing an attachment—strongly suggests this is an announcement about a regulatory event rather than the full regulatory filing itself. The content specifically concerns a change in significant shareholding/voting rights (Art. 69 of the Polish Public Offering Act). This aligns best with the 'Major Shareholding Notification' (MRQ) category, which covers changes in significant ownership levels crossing thresholds. Since the document is an announcement of a notification, and MRQ covers changes in significant share ownership, MRQ is the most appropriate specific code. If MRQ were not available, RNS would be a fallback, but MRQ is more precise here.
2022-02-08 Polish
Uzyskanie zgody na przeprowadzenie badania na pacjentach klinicznych dla kandydata na produkt leczniczy BCX-CM-AD - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement in Polish by the Management Board ('Zarząd') of Bioceltix S.A. regarding obtaining approval from the Local Ethics Committee ('Lokalnej Komisji Etycznej' - LKE) to conduct a planned clinical trial for a veterinary medicinal product candidate (BCX-CM-AD) for canine atopic dermatitis. The text details the purpose, location, methodology (patient groups, observation time), and significance of this regulatory/ethical approval step for the product's development and potential commercialization. This type of announcement, detailing progress in product development, regulatory hurdles, or clinical trials, fits best under the general category of Regulatory Filings (RNS) or potentially Legal Proceedings Report (LTR) if it were about a dispute, but here it is a positive regulatory milestone. Given the options, and since it is a specific regulatory/ethical approval announcement that doesn't fit the other specific categories (like ER, 10-K, DIV, etc.), the most appropriate fallback is Regulatory Filings (RNS). It is not a standard financial report, management change, or dividend notice. The document length is short (1777 chars), but it is the substance of the filing itself, not an announcement *about* another report, so RPA is not appropriate.
2022-02-07 Polish
Otrzymanie raportu końcowego z badania fazy bezpieczeństwa kandydata na produkt leczniczy BCX-CM-J - Content (PL)
Report Publication Announcement Classification · 1% confidence The document is very short (863 characters) and announces the receipt of a final report ('raport końcowy') regarding a safety study (TAS) for a drug candidate (BCX-CM-J). It references a previous current report (raport bieżący) and states that the receipt of this final report formally closes the study. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report has been received or published, without containing the full content of that report, should be classified as a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Since this is a specific announcement about the finalization/receipt of a study report, RPA is the most appropriate classification, as it announces the publication/finalization of a key document.
2022-02-03 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.